SG10201408483QA - Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc - Google Patents

Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc

Info

Publication number: SG10201408483QA
Authority: SG; Singapore
Prior art keywords: cdb; dysmenorrhea; endometriosis; treatment; breast cancer
Prior art date: 2008-04-28

Application number

SG10201408483QA

Inventor

Joseph S Podolski

Original Assignee

Repros Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-04-28

Filing date

2009-04-27

Publication date

2015-02-27

2009-04-27 Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc

2015-02-27 Publication of SG10201408483QA publication Critical patent/SG10201408483QA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)

SG10201408483QA 2008-04-28 2009-04-27 Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc SG10201408483QA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US4847208P	2008-04-28	2008-04-28

Publications (1)

Publication Number	Publication Date
SG10201408483QA true SG10201408483QA (en)	2015-02-27

Family

ID=40751037

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG10201408483QA SG10201408483QA (en)	2008-04-28	2009-04-27	Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc

Country Status (24)

Country	Link
US (2)	US8426394B2 (en)
EP (1)	EP2293797B1 (en)
JP (1)	JP5791499B2 (en)
KR (2)	KR20130059442A (en)
CN (2)	CN105616427A (en)
AR (1)	AR071516A1 (en)
AU (1)	AU2009241355B2 (en)
BR (1)	BRPI0911563A2 (en)
CA (1)	CA2722753C (en)
CL (1)	CL2009001010A1 (en)
DK (1)	DK2293797T3 (en)
EA (3)	EA201990835A3 (en)
ES (1)	ES2561810T3 (en)
IL (1)	IL208844A0 (en)
ME (1)	ME01123B (en)
MX (1)	MX2010011272A (en)
MY (1)	MY161059A (en)
NI (1)	NI201000183A (en)
NZ (1)	NZ589533A (en)
SG (1)	SG10201408483QA (en)
TW (1)	TWI477276B (en)
UA (1)	UA102849C2 (en)
WO (1)	WO2009134718A1 (en)
ZA (1)	ZA201007529B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI477276B (en)	2008-04-28	2015-03-21	Repros Therapeutics Inc	Antiprogestin dosing regimens
TWI539953B (en) *	2008-04-28	2016-07-01	瑞波若斯治療學公司	Compositions and methods for treating breast cancer
HUP0900487A2 (en) *	2009-08-05	2011-03-28	Richter Gedeon Nyrt	17-acetoxy-11ß-[4-(dimethyl-amino)-phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione new crystalline polymorphic modification and process for preparation
UA113283C2 (en) *	2010-12-23	2017-01-10		19-NORSTEROIDS AND THEIR APPLICATIONS FOR THE TREATMENT OF PROGESTERON-STAINLESS STATES
EP2471537A1 (en) *	2010-12-30	2012-07-04	PregLem S.A.	Treatment of pain associated with dislocation of basal endometrium
BR112014012444B1 (en)	2011-11-23	2021-12-14	Therapeuticsmd, Inc	A PHARMACEUTICAL COMPOSITION COMPRISING SOLUBILIZED ESTRADIOL, PROGESTERONE AND A SOLUBILIZING AGENT, AND USES THEREOF TO TREAT A MENOPAUSE-RELATED SYMPTOM IN A WOMAN
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
BR112014029131B1 (en) *	2012-05-31	2021-03-09	Allergan Pharmaceuticals International Limited	mucoadhesive capsule
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
HK1211852A1 (en)	2012-11-02	2016-06-03	Repros Therapeutics Inc.	Methods and compositions for treating progesterone-dependent conditions
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
HU230381B1 (en) *	2014-02-17	2016-03-29	Richter Gedeon Nyrt	Process for producing steroid intermediate
CA2947767A1 (en)	2014-05-22	2015-11-26	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10098894B2 (en)	2014-07-29	2018-10-16	Therapeuticsmd, Inc.	Transdermal cream
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
WO2017173044A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Steroid hormone compositions in medium chain oils
WO2017173071A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2377418A1 (en) *	1977-01-13	1978-08-11	Roussel Uclaf	NEW 4,9-DIENIC 11B-SUBSTITUTE STEROID DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICINAL PRODUCTS
FR2521565B1 (en)	1982-02-17	1985-07-05	Dior Sa Parfums Christian	PULVERULENT MIXTURE OF LIPID COMPONENTS AND HYDROPHOBIC CONSTITUENTS, METHOD FOR PREPARING SAME, HYDRATED LIPID LAMELLAR PHASES AND MANUFACTURING METHOD, PHARMACEUTICAL OR COSMETIC COMPOSITIONS COMPRISING HYDRATED LAMID PHASES
FR2522328B1 (en)	1982-03-01	1986-02-14	Roussel Uclaf	NEW PRODUCTS DERIVED FROM THE STRUCTURE 3-CETO 4,9 19-NOR STEROIDS, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS
FR2534487B1 (en)	1982-10-15	1988-06-10	Dior Christian Parfums	METHOD FOR THE HOMOGENEIZATION OF HYDRATED LIPIDAL LAMELLAR PHASE DISPERSIONS, AND SUSPENSIONS OBTAINED THEREBY
EP0501523B1 (en)	1983-11-14	1997-04-09	Columbia Laboratories, Inc.	Bioadhesive compositions
FR2598421B1 (en)	1986-05-06	1988-08-19	Roussel Uclaf	NOVEL 19-NOR OR 19-NOR D-HOMO STEROIDS SUBSTITUTED IN POSITION 11B BY A RADICAL PHENYL CARRYING AN ALKYNYL RADICAL, THEIR PREPARATION METHOD, THEIR APPLICATION AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM
US5077211A (en)	1988-07-06	1991-12-31	Applied Genetics, Inc.	Purification and administration of dna repair enzymes
US5439913A (en) *	1992-05-12	1995-08-08	Schering Aktiengesellschaft	Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5468741A (en)	1993-05-28	1995-11-21	The Regents Of The University Of California	Use of low levels of mifepristone to treat leiomyomata
HUT74465A (en) *	1993-11-16	1996-12-30	Schering Ag	Pharmaceutical composition which useable for treatment of uterine contractility disorders containing a nitric oxide synthase substrate and/or donor, or a nitric oxide inhibitor
DE4426601A1 (en) *	1994-07-27	1996-02-01	Schering Ag	Use of a combination product containing a competitive progesterone antagonist and a progestogen for the manufacture of a medicament for the treatment of endometriosis or Leiomyomata uteri
MX9603889A (en) *	1995-02-02	1997-04-30	Schering Ag	Progesterone antagonists useful for preparing medicaments for treating dysfunctional uterine bleeding.
JP4260886B2 (en) *	1996-05-01	2009-04-30	アメリカ合衆国	21-Substituted progesterone derivatives as novel anti-progesterone
US6900193B1 (en) *	1996-05-01	2005-05-31	The United States Of America As Represented By The Department Of Health And Human Services	Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
WO1998008471A1 (en)	1996-08-30	1998-03-05	The Population Council, Inc.	Vaginal application mifepristone
US6020328A (en)	1998-03-06	2000-02-01	Research Triangle Institute	20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6172052B1 (en)	1998-12-04	2001-01-09	Research Triangle Institute	17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP1008443A1 (en)	1998-12-08	2000-06-14	Alusuisse Technology & Management AG	Sterilisable multilayer film for packaging
US6740645B1 (en)	1999-09-03	2004-05-25	Research Triangle Institute	17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
ES2546291T3 (en) *	2000-03-17	2015-09-22	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	17-Alpha-substituted, 11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienodiones as antiprogestational agents
IN191020B (en) *	2000-03-28	2003-09-13	Dabur Res Foundation
WO2001074684A2 (en)	2000-04-03	2001-10-11	Astenjohnson, Inc.	Pre-crimped tie components
CN1512886A (en) *	2000-10-18	2004-07-14	��ֹɷݹ�˾	Use of antiprogestins for the prevention and treatment of hormone-dependent diseases
CA2777199A1 (en)	2001-07-09	2003-01-23	Repros Therapeutics Inc.	Methods and materials for the treatment of testosterone deficiency in men
EP1620060B1 (en)	2003-04-29	2010-03-24	The General Hospital Corporation	Methods and devices for the sustained release of multiple drugs
EP1593376A1 (en)	2004-05-04	2005-11-09	Warner-Lambert Company LLC	Improved pullulan capsules
WO2006010097A2 (en) *	2004-07-09	2006-01-26	The Population Council, Inc.	Sustained release compositions containing progesterone receptor modulators
GT200500185A (en) *	2004-08-09	2006-04-10		PROGESTERONE RECEIVER MODULATORS UNDERSTANDING PIRROL-OXINDOL DERIVATIVES AND THEIR USES
DE102005028970A1 (en) *	2005-06-22	2006-12-28	Siemens Ag	Piezoelectric actuator with increased lifting capacity
DE102005030294A1 (en) *	2005-06-24	2007-01-04	Schering Ag	Nonsteroidal progesterone receptor modulators
WO2007103510A2 (en) *	2006-03-08	2007-09-13	Danco Laboratories Llc	Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
MX343130B (en) *	2006-10-24	2016-10-26	Repros Therapeutics Inc	Compositions and methods for suppressing endometrial proliferation.
MX2009007313A (en) *	2007-01-17	2009-07-15	Repros Therapeutics Inc	Methods for improved stability of steroid derivatives.
EP2144601A4 (en)	2007-04-05	2012-10-10	Univ Kansas	FAST RESOLVING PHARMACEUTICAL COMPOUNDS WITH PULLULAN
CA2684450C (en)	2007-04-20	2017-05-30	Preglem S.A.	Progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding
TWI477276B (en)	2008-04-28	2015-03-21	Repros Therapeutics Inc	Antiprogestin dosing regimens
EP2482914A1 (en)	2009-09-29	2012-08-08	Koninklijke Philips Electronics N.V.	Intrauterine electronic capsule for administering a substance

2009
- 2009-04-09 TW TW098111780A patent/TWI477276B/en not_active IP Right Cessation
- 2009-04-27 EA EA201990835A patent/EA201990835A3/en unknown
- 2009-04-27 MX MX2010011272A patent/MX2010011272A/en active IP Right Grant
- 2009-04-27 ES ES09739520.6T patent/ES2561810T3/en active Active
- 2009-04-27 US US12/990,203 patent/US8426394B2/en not_active Expired - Fee Related
- 2009-04-27 SG SG10201408483QA patent/SG10201408483QA/en unknown
- 2009-04-27 CA CA2722753A patent/CA2722753C/en not_active Expired - Fee Related
- 2009-04-27 JP JP2011506497A patent/JP5791499B2/en not_active Expired - Fee Related
- 2009-04-27 KR KR1020137009925A patent/KR20130059442A/en not_active Ceased
- 2009-04-27 CN CN201610029200.9A patent/CN105616427A/en active Pending
- 2009-04-27 EA EA201071249A patent/EA201071249A1/en unknown
- 2009-04-27 AU AU2009241355A patent/AU2009241355B2/en not_active Ceased
- 2009-04-27 UA UAA201014039A patent/UA102849C2/en unknown
- 2009-04-27 WO PCT/US2009/041826 patent/WO2009134718A1/en not_active Ceased
- 2009-04-27 DK DK09739520.6T patent/DK2293797T3/en active
- 2009-04-27 NZ NZ589533A patent/NZ589533A/en not_active IP Right Cessation
- 2009-04-27 BR BRPI0911563A patent/BRPI0911563A2/en not_active Application Discontinuation
- 2009-04-27 ME MEP-2010-182A patent/ME01123B/en unknown
- 2009-04-27 CN CN2009801149788A patent/CN102014923A/en active Pending
- 2009-04-27 EA EA201401347A patent/EA032646B1/en not_active IP Right Cessation
- 2009-04-27 MY MYPI2010004777A patent/MY161059A/en unknown
- 2009-04-27 KR KR20107026587A patent/KR20110014162A/en not_active Ceased
- 2009-04-27 EP EP09739520.6A patent/EP2293797B1/en not_active Not-in-force
- 2009-04-28 CL CL2009001010A patent/CL2009001010A1/en unknown
- 2009-04-28 AR ARP090101513 patent/AR071516A1/en unknown
2010
- 2010-10-20 IL IL208844A patent/IL208844A0/en unknown
- 2010-10-21 ZA ZA2010/07529A patent/ZA201007529B/en unknown
- 2010-10-27 NI NI201000183A patent/NI201000183A/en unknown
2013
- 2013-04-02 US US13/855,559 patent/US8735381B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MY161059A (en)	2017-04-14
US8426394B2 (en)	2013-04-23
BRPI0911563A2 (en)	2016-07-12
EP2293797B1 (en)	2015-11-11
CN102014923A (en)	2011-04-13
TW200950786A (en)	2009-12-16
CA2722753C (en)	2018-07-03
CA2722753A1 (en)	2009-11-05
MX2010011272A (en)	2010-12-21
EA032646B1 (en)	2019-06-28
EA201990835A3 (en)	2019-12-30
DK2293797T3 (en)	2016-01-11
EA201990835A2 (en)	2019-08-30
AR071516A1 (en)	2010-06-23
IL208844A0 (en)	2011-01-31
ES2561810T3 (en)	2016-03-01
US20110046098A1 (en)	2011-02-24
WO2009134718A1 (en)	2009-11-05
JP2011518845A (en)	2011-06-30
ME01123B (en)	2013-03-20
AU2009241355A1 (en)	2009-11-05
US8735381B2 (en)	2014-05-27
EP2293797A1 (en)	2011-03-16
US20130289008A1 (en)	2013-10-31
UA102849C2 (en)	2013-08-27
AU2009241355B2 (en)	2013-11-14
ZA201007529B (en)	2011-07-27
KR20130059442A (en)	2013-06-05
KR20110014162A (en)	2011-02-10
JP5791499B2 (en)	2015-10-07
CN105616427A (en)	2016-06-01
NZ589533A (en)	2012-06-29
EA201071249A1 (en)	2011-08-30
CL2009001010A1 (en)	2009-06-19
NI201000183A (en)	2012-06-06
WO2009134718A8 (en)	2010-09-23
TWI477276B (en)	2015-03-21
EA201401347A1 (en)	2015-07-30

Publication	Publication Date	Title
SG10201408483QA (en)	2015-02-27	Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc
IL247093A0 (en)	2016-09-29	Progesterone antagonists such as cdb-4124 in the treatment of breast cancer
GB2458210C (en)	2018-05-30	Underwear garment
EP2240257A4 (en)	2010-10-20	Rocks and aggregate, and methods of making and using the same
GB0802486D0 (en)	2008-03-19	Warm water economy device
ZA201006049B (en)	2011-05-25	Use of ulipristal for treating uterine fibroids
PL2451328T3 (en)	2013-03-29	Mixing device
SI2376020T1 (en)	2017-07-31	Vaginal device
PT2315773T (en)	2016-11-23	Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis
EP2350255A4 (en)	2013-07-31	Polyaluminum compositions
PT2482841T (en)	2019-03-01	Compositions and methods for enhancing coagulation factor viii function
PL2367850T3 (en)	2015-12-31	Human anti tshr antibodies
GB0810252D0 (en)	2008-07-09	Device for preparing bone cement
IL200764A (en)	2017-01-31	Composition comprising epha3 antibodies for use in the treatment of solid tumors
GB0807555D0 (en)	2008-06-04	Two-chamber coaxial electrolyser device
EP2493291A4 (en)	2013-08-21	Peham dendrimers for use in agriculture
GB2473145B (en)	2012-06-27	Self-collimator planar spectroscopy shaping device for chirped-pulse-amplificaition
PL2242566T3 (en)	2021-05-17	Hybrid mixer
ZA201103627B (en)	2012-09-26	Prophylactic/therapeutic agent for cancer
IL200380A0 (en)	2010-04-29	Mineralcorticoid receptor antagonists for the treatment of endometriosis
GB0805848D0 (en)	2008-04-30	Device interconnects
EP2110036A4 (en)	2015-07-01	Girdle for garments
EP2450352A4 (en)	2013-01-30	PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER
ZA201200371B (en)	2012-09-26	Anti-filming surface-active agent
SI2482784T1 (en)	2013-11-29	Device which permits slimming by improving blood flow in the abdomen area